#Germany #biopharmaceuticals #Heidelberg #ProtaGene #ISA Testing

ProtaGene's Recent Milestone in Gene Therapy Testing

In a significant advancement for gene therapy, ProtaGene has recently achieved accreditation from the Clinical Laboratory Improvement Amendments (CLIA) and the College of American Pathologists (CAP) for its Heidelberg laboratory. This prestigious certification enables ProtaGene to conduct Integration Site Analysis (ISA) on human samples treated with lentivirus-based cell and gene therapy products. This approval is not just a formality; it underscores the company's commitment to adhering to the highest quality and regulatory standards in the biopharmaceutical sector.

Importance of CAP and CLIA Accreditation

The CAP accreditation affirms ProtaGene's dedication to laboratory excellence, following an extensive evaluation of its practices, systems, and personnel. It serves as a recognized benchmark in the industry, validating that the laboratory meets stringent federal regulatory standards for testing on human specimens. Richard Gabriel, the Vice-President of Research and Development at ProtaGene, stated, "Reaching this milestone reflects our team's commitment to patient safety in cell and gene therapy, driven by adherence to the highest quality standards and the delivery of best-in-class, industry-leading safety analyses."

This accreditation allows ProtaGene to expand its ISA services significantly. The company tailors these services to meet the varying needs of its clients, which encompasses everything from the initial sample receipt to the final report delivery. Each step, including sample quality control, library preparation, next-generation sequencing, bioinformatics analysis, and reporting, is conducted with the utmost precision.

Contributing to Safer Gene Therapies

ProtaGene aims to enhance the safety of gene therapies by delivering critical data that supports safety assessments for various cell and gene therapies, including those involving viral vectors and non-viral approaches. The company boasts superior assay performance across a wide variety of viral vectors and has pioneered the first ICH-validated ISA methodology, enabling faster regulatory approvals for its clients.

The significance of ProtaGene's approach is evident in its commitment to enabling quicker turnaround times for testing, which is crucial in a field where advancements are rapid, and patient safety is paramount.

A Trusted Partner in Biopharmaceuticals

With this latest achievement, ProtaGene solidifies its role as a leader in the biopharmaceutical industry. Dr. Michael Stump, President of ProtaGene US, noted, "Achieving CLIA accreditation highlights our role as a trusted biopharma partner, advancing safe therapies through reliable, high-quality analytics." This strategic position as a reliable partner reflects ProtaGene's deep understanding of the complexities involved in the development of safe and effective gene therapies.

About ProtaGene

ProtaGene stands as a premier Contract Research Organization (CRO) dedicated to the biopharmaceutical and cell and gene therapy sectors. The company offers groundbreaking, integrated solutions with comprehensive protein and gene analytic capabilities, supporting clients from the discovery phase right through to commercialization. With four operational sites in Europe and North America, ProtaGene collaborates with leading biopharmaceutical and gene therapy companies around the globe, maintaining its status as a premier service provider within the industry.

For further details about ProtaGene and its services, visit their official website at www.protagene.com or connect with them on LinkedIn.